Cagri-RC

This amylin / calcitonin receptor agonist reference standard is a synthetic peptide analog of the pancreatic hormone amylin, engineered with backbone-stabilizing substitutions and a fatty-diacid acylation moiety that confers extended plasma residence through albumin binding. The peer-reviewed literature catalogs the molecule across amylin-receptor pharmacology investigations, calcitonin-receptor crosstalk studies, and metabolic-pathway research where amylin-class signaling is dissected from incretin-pathway engagement. Investigators frequently characterize the molecule in comparative or combination paradigms alongside GLP-1R agonists. Molecular identity is fixed by sequence and structural confirmation against PubChem CID 171397054, empirical formula C194H312N54O59S2, with CAS Registry Number 1415456-99-3. Supplied for laboratory characterization, in-vitro receptor-binding work, and in-cell signaling studies only. For research use only; not for human consumption, medical use, or veterinary application. Researchers should consult primary literature for context-specific experimental conditions.

The molecule is a multi-residue cyclic peptide whose intramolecular disulfide bridge preserves the bioactive conformation characteristic of native amylin while incorporating substitutions that resist enzymatic degradation. A γ-glutamic-acid-linked C20 fatty diacid moiety on a lysine side chain drives high-affinity reversible albumin binding, producing a pharmacokinetic profile documented in the literature as multi-day plasma residence. The molecule engages amylin receptors — RAMP1, RAMP2, and RAMP3 complexes formed with the calcitonin receptor — and is documented across published binding-affinity studies for differential engagement of these receptor heteromers. Interaction profile spans Gs-coupled cAMP activation downstream of amylin-receptor engagement, calcitonin-receptor crosstalk, and metabolic-pathway research in cell-culture and animal-model contexts. All activity descriptors here are framed as documented in published work. Structural confirmation is established by mass spectrometry and HPLC-validated purity on each Certificate of Analysis.

Experimental domains documented in the published literature include amylin-receptor binding-affinity studies across RAMP1 / RAMP2 / RAMP3 calcitonin-receptor heteromers, structure-activity investigations dissecting the intramolecular disulfide and acylation contributions, β-cell co-stimulation studies in pancreatic-islet preparations, comparative work alongside native amylin and other amylin-class research analogs, combination paradigms with GLP-1R agonists for combined amylin-and-incretin pathway research, and metabolic-pathway investigations in animal-model contexts. Investigators have also characterized the molecule in studies of receptor desensitization and in screening assays for amylin-class ligand discovery. Use in laboratory research extends to mechanism-elucidation paradigms where the construct serves as a defined extended-residence amylin-receptor agonist. The reference standard is supplied for these and equivalent in-vitro and animal-model experimental contexts only, with no associated guidance for human, clinical, or veterinary application.

Each lot is characterized by reverse-phase HPLC for chromatographic purity and by mass spectrometry for molecular-ion confirmation against the C194H312N54O59S2 empirical formula. Purity is reported as an HPLC-area percentage on the Certificate of Analysis distributed with every lot, alongside the molecular-weight match within instrument tolerance. Disulfide-bond integrity is confirmed by reduction-and-alkylation mass spectrometry methods when included in the lot's release specification. The acylation site and fatty-diacid stoichiometry are confirmed by tandem mass spectrometry when included in the release specification. Peptide content where applicable is determined by amino-acid analysis or nitrogen-content assay following the analytical method specified on the COA. The COA records the lot identifier, manufacturing date, and analytical method versions used. Researchers requiring batch-level analytical detail should reference the COA distributed with the supplied material.

For laboratory storage, the lyophilized reference standard should be held at −20°C in its sealed, light-protected container until ready for analytical use. Allow vials to equilibrate to ambient temperature before opening to avoid moisture condensation on the lyophile. Reconstitution for in-vitro experimental use is typically performed in bacteriostatic water or a researcher-selected buffer compatible with the downstream assay; once reconstituted, store the working solution at 2–8°C and characterize stability in the relevant buffer prior to extended storage. The intramolecular disulfide bridge is sensitive to reducing conditions — avoid reductant-containing buffers unless specifically required by the downstream assay. Avoid repeated freeze-thaw cycles of reconstituted material. These handling parameters reflect general best-practice for cyclic acylated peptide reference standards and do not constitute preparation guidance for human or veterinary application.